Associated Papers
Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.
Riedl JM et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
Kwon JJ et al.
Biorxiv : the Preprint Server for Biology, 2024
39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_3.xlsx › KRAS_G12D_LOF_DMS_Screens
Site-specific mutagenesis screening in KRASG12D mutant library to uncover resistance mechanisms to KRASG12D inhibitors.
Choi J et al.
Cancer Letters, 2024
Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A et al.
Biomarker Research, 2024
Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene-A Literature Review and Single-Center Experience.
Rekowska AK et al.
Biomedicines, 2024
Assessment of KRASG12C inhibitors for colorectal cancer.
Piazza GA et al.
Frontiers in Oncology, 2024
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
Sacher A et al.
The New England Journal of Medicine, 2023
Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M et al.
Current Treatment Options in Oncology, 2022
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance.
Reita D et al.
Cancers, 2022
Understanding the influence of AMG 510 on the structure of KRASG12C empowered by molecular dynamics simulation.
Li Y et al.
Computational and Structural Biotechnology Journal, 2022
35284050 (PubMed )
Supplement: mmc1.docx
Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours.
Velho S et al.
Human Molecular Genetics, 2010
Select a paper to view details